{"id":"W1433367056","doi":"10.1182/blood.v124.21.2292.2292","title":"Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Blinatumomab; Medicine; Refractory (planetary science); Internal medicine; Cytokine release syndrome; Dosing; Hematopoietic stem cell transplantation; Clinical endpoint; Acute lymphocytic leukemia; Phases of clinical research; Bone marrow; Salvage therapy; Gastroenterology; Adverse effect; Transplantation; Toxicity; Oncology; Leukemia; Clinical trial; Chemotherapy; Lymphoblastic Leukemia; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001810429,0.001505495,0.00192969,0.0003691848,0.0004942961,0.0009249062,0.0007780419,0.0009892404,0.003467157],"category_scores_gemma":[0.0008059668,0.0005587861,0.0009474962,0.0004029467,0.0007031929,0.0007824823,0.0003932978,0.003011481,0.0009141889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009391489,"about_ca_system_score_gemma":0.002232487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009282291,"about_ca_topic_score_gemma":0.002196033,"domain_scores_codex":[0.9994899,0.0002647456,0.00002212858,0.00008470788,0.00004841751,0.00009012895],"domain_scores_gemma":[0.9993756,0.00008456712,0.0001152945,0.00006611721,0.00005821821,0.0003001197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.497764,0.1940048,0.03595547,0.001278158,0.001628918,0.001088157,0.0009719704,0.003241051,0.1263684,0.0006811836,0.00932668,0.1276911],"study_design_scores_gemma":[0.2544652,0.7039764,0.02410684,0.00004073412,0.0005402561,0.0009235622,0.0001219966,0.0008543876,0.007057475,0.000199761,0.007683903,0.00002955985],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922962,0.0008847751,0.0005057202,0.000338452,0.00006048558,0.003647752,0.001221153,0.0000703344,0.0009750679],"genre_scores_gemma":[0.9793767,0.001796075,0.003610993,0.001116325,0.000210983,0.006969361,0.004239206,0.00005478934,0.002625609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003467157,"threshold_uncertainty_score":0.01159877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01093151886360859,"score_gpt":0.269033386135677,"score_spread":0.2581018672720684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}